The invention relates to pharmaceutical preparation containing a 17a-acyloxy-6-methyl-16-methylene-pregna-4,6-diene-3,20-dione compound as an active ingredient, and to the use of such preparations for the palliative treatment and control of certain types of neoplasmin conditions.

A pharmaceutical tablet is produced which comprises 10% to 70% urea, and at least 20% of a .beta.-lactam antibiotic.

Tricyclic pyrazole derivatives of the following formula (I) having affinity for the cannabinoidergic CB1 and/or CB2 receptors: ##STR00001## wherein: A represents a group selected from one of the following: (CH.sub.2).sub.t--, --(CH.sub.2)--S(O).sub.z--, or --S(O).sub.z--(CH.sub.2)--, B is a heteroaryl, optionally substituted; R is a group selected from the following: alkyl, aryl, arylalkyl or arylalkenyl, not substituted or having from one to four substituents, equal to or different from each ot...

Dichloromethane diphosphonates affect the biosynthesis of collagen.

A pharmaceutical composition for oral administration in dosage unit form which comprises at least one xanthine derivative selected from the group consisting of (a) (.omega.-1(-hydroxyalkyl-dialkylxanthines wherein the (.omega.-1)-hydroxyalkyl group contains 5 or 6 carbon atoms and is in the 1- or 7-position, the alkyl group in the other of the 1- and 7-position contains from 1 to 12 carbon atoms and the alkyl group in the 3-position contains from 1 to 4 carbon atoms, (b) (.omega.-1)-oxoalkyl-dim...

The use of 1-(p-.beta.-dimethylaminoethoxyphenyl)-trans-1-(p-hydroxyphenyl)-2-phenylb ut-1-ene as an anti-oestrogenic agent and pharmaceutical compositions containing this compound.

A cardiotonic dosage unit form comprises a soft gelatin capsule containing a liquid cardiotonic composition comprising (a) a cardiac glycoside, preferably digitoxin or digoxin; (b) ethanol; (c) water; (d) propylene glycol and/or glycerine; and (e) a liquid polyethylene glycol; the cardiac glycoside preferably being present in an amount of from 50 to 300 micrograms.

The invention concerns pharmaceutical compositions having analgesic, and in some cases, in addition anti-inflammatory properties, for use in the treatment of painful inflammatory joint disease, which compositions contain as active ingredient a new or old 1-alkyl (or cycloalkyl)-4-(N-alkanoyl)substituted-amino-tetrahydro-1,3,5-triazine-2,6- dione of the formula: ##STR1## or a base-addition salt thereof. Many of the compounds of formula I are previously known as herbicides, and a representative ex...

Anti-inflammatory compositions are prepared which comprise a therapeutically effective effective amount of a compound of the formula ##STR1## wherein X is CO; Y is an oxygen atom; the dotted line represents a double bond which is present or absent; R.sub.1 is hydrogen or methyl; R.sub.2 is hydrogen; and R.sub.3 is phenyl unsubstituted or substituted by 1 or 2 substituents selected from the group consisting of fluorine, chlorine, bromine, methyl, ethyl, methoxyl, ethoxyl, benzyloxyl, hydroxyl, ac...

Combinations comprising an anti-aggregatory substance together with one or more of an anti-oxidant and a thromboxane A.sub.2 synthetase inhibitor are disclosed. Combinations are useful for the treatment/prophylaxis of disorders attributable to blood platelet aggregation.